共 326 条
[1]
André T(2020)Pembrolizumab in microsatellite-instability-high advanced colorectal cancer N Engl J Med 383 2207-2218
[2]
Shiu K-K(2022)PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer N Engl J Med 386 2363-2376
[3]
Kim TW(2020)Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603) J Clin Oncol 38 2053-2061
[4]
Jensen BV(2008)PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677-704
[5]
Jensen LH(2019)The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors J Immunother Cancer 7 278-1287
[6]
Punt C(2015)PD-L1 expression as a potential predictive biomarker Lancet Oncol 16 1285-608
[7]
Cercek A(2021)Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer J Immunother Cancer 9 e002230-1285
[8]
Lumish M(2020)Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas Ann Oncol Off J Eur Soc Med Oncol 31 599-153
[9]
Sinopoli J(2020)Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers J Immunother Cancer 8 e001558-60
[10]
Weiss J(2019)Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma BMC Cancer 19 360-215